PCI Biotech to present at BIOTrinity 2016

Oslo, April 26, 2016 – PCI Biotech will present at BIOTrinity 2016 on Tuesday, April 26, 2016 at 15:50 p.m. local time at Novotel London West, UK.

BioTrinity 2016 is Europe’s leading investment and biopartnering conference. The presentation will be held by Mr. Gaël L’Hévéder, CBDO and the presentation is available below.

PCI Biotech BioTrinity April 2016 presentation

About PCI Biotech

PCI Biotech is a cancer focused biopharmaceutical company headquartered in Norway and listed on the Oslo Stock Exchange (Axess). The company is developing therapeutic products based on its proprietary photochemical internalisation (PCI) technology. The PCI technology works by inducing triggered endosomal release and may be used to unlock the true potential of a wide array of therapeutic modalities, such as small molecules, vaccines and nucleic acids.

The company has a clinical Phase I/II program in bile duct cancer, which is an orphan indication without approved medicinal products and a high need for better local treatments. The indication is well suited for PCI treatment, with easy light access through routine endoscopic methods and an active generic drug (gemcitabine) significantly enhanced by PCI.

The company is also developing PCI as a vaccination technology. When applied in the emerging field of cancer immunotherapy, PCI can be used to enhance the important cytotoxic effect of therapeutic cancer vaccines.

The PCI technology is also very well suited for intracellular delivery of nucleic acids, such as RNA therapeutics. By releasing nucleic acid compounds from endosomes where they are trapped following administration, PCI addresses one of the major bottlenecks facing this emerging and exciting field.

Contact information:
PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo
Per Walday, CEO, pw@pcibiotech.no, Mobile: +47 917 93 429